Robert Weisman

Weisman covers the healthcare and life sciences industries for the Business section. He was a business reporter and editor for the Hartford Courant and the Seattle Times before joining the Globe in 2000.

Latest stories

Five Things You Should Know About... Michael Schopperle

By , Globe Staff

CureMeta LLC’s W. Michael Schopperle started the Boston biotech with the goal of developing novel diagnostics and therapies for aggressive metastatic cancers.

Field of genes: Cultivating biopharma, bio-ag links

By , Globe Staff

Until recently, the Boston area investors who bankroll drug discovery have shied away from bio-agriculture. But that may be starting to change

As Biogen CEO steps down, analysts see challenges ahead

By , Globe Staff

The Cambridge biotech giant is financial sound but must address waning sales growth and limited near-term prospects for new blockbuster products.

Big Pharma’s cash flows in a flurry of partnerships

By , Globe Staff

Striking development deals has become a rite of passage for local biotechs.